Sativex is indicated for spasticity in MS patients who have not responded adequately to other treatments.
It is administered as oromucosal spray enabling flexible dosage, which is particularly appropriate given the variable nature of spasticity and MS itself.
Evidence from clinical trials shows that Sativex has a positive impact on spasticity, sleep quality and mobility and enables patients to carry out everyday tasks such as getting up, getting dressed or washed.
Sativex is an endocannabinoid modulator made of two actives – THC (delta-9-tetrahidrocannabinol) and CBD (cannabidiol)-, which was developed and is manufactured by GW Pharmaceuticals, UK.
Almirall holds marketing rights in Europe (except UK).